Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

403
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
403
Drug Classes and Categories01:25

Drug Classes and Categories

2.3K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.3K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.0K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term postmarketing safety of psoriasis treatments on autoimmune disease risk: a 15-year nationwide cohort study in Denmark.

Skin health and disease·2026
Same author

C-Reactive Protein and Long-Term Risk of Death in Patients with Myocardial Infarction.

Cardiology·2026
Same author

Epidemiology of atopic dermatitis.

Journal of the American Academy of Dermatology·2026
Same author

The Burden of Eczema (Atopic Dermatitis) in Canadian Adults: A Cross-Sectional Survey.

Journal of cutaneous medicine and surgery·2026
Same author

Risk of hidradenitis suppurativa in patients with juvenile arthritis: A nationwide cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings.

BMJ open·2026
Same journal

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026
Same journal

Patient Engagement With Dermatology Notes in the Electronic Patient Portal.

JAMA dermatology·2026
Same journal

Melasma.

JAMA dermatology·2026
Same journal

It Is Time to End Routine Laboratory Monitoring for Isotretinoin.

JAMA dermatology·2026
Same journal

Rapidly Enlarging Erythematous Plaque of the Forearm in an Older Man.

JAMA dermatology·2026
Same journal

ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence.

JAMA dermatology·2026
See all related articles

Related Experiment Video

Updated: Sep 22, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

507

Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems.

Alexa C Bowie1, Mina Tadrous1,2,3, Alexander Egeberg4

  • 1Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.

JAMA Dermatology
|May 25, 2022
PubMed
Summary
This summary is machine-generated.

Topical corticosteroid potency classifications show low-to-moderate agreement but strong correlation across systems. Researchers must be transparent about their chosen classification for topical corticosteroids in studies.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

351

Related Experiment Videos

Last Updated: Sep 22, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

507
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

351

Area of Science:

  • Dermatology
  • Pharmacology
  • Epidemiology

Background:

  • Topical corticosteroids (TCSs) vary in potency, affecting efficacy and safety.
  • Lack of a universal TCS potency classification hinders pharmacoepidemiologic research and clinical interpretation.

Purpose of the Study:

  • To classify TCS formulations into three common potency systems.
  • To evaluate agreement and correlation between these TCS classification systems.

Main Methods:

  • Compiled a list of 232 unique TCS formulations from multiple sources.
  • Classified TCSs using the 7-category US system, a 4-category Cochrane review system, and the 4-category WHO ATC system.
  • Analyzed agreement using Cohen weighted kappa (κw) and correlation using Spearman rank coefficients (r).

Main Results:

  • Found low-to-moderate agreement between the classification systems (κw range: 0.53-0.60).
  • Observed strong correlations between all pairs of systems (r range: 0.71-0.77).
  • The US classification showed weak agreement with ATC and moderate with Cochrane, while correlations were strong across all.

Conclusions:

  • Existing TCS potency classification systems are often incongruent, potentially leading to varied pharmacoepidemiologic study results.
  • Transparency in classification methods is crucial for researchers.
  • Consideration of alternative potency definitions in sensitivity analyses is recommended.